These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Immortalization of antigen selected B cells. Steenbakkers PG; van Wezenbeek PM; Olijve W J Immunol Methods; 1993 Jul; 163(1):33-40. PubMed ID: 7687638 [TBL] [Abstract][Full Text] [Related]
4. Humoral immunity to the human immunodeficiency virus. Weber J Curr Opin Immunol; 1989-1990 Feb; 2(3):420-3. PubMed ID: 2483884 [No Abstract] [Full Text] [Related]
5. How does the HIV escape cytotoxic T cell immunity? Phillips RE; McMichael AJ Chem Immunol; 1993; 56():150-64. PubMed ID: 7680867 [No Abstract] [Full Text] [Related]
6. [AIDS vaccines: an enigma in vaccine development]. Dorner F; Barrett N Wien Klin Wochenschr; 1990 Jan; 102(2):51-8. PubMed ID: 1689919 [TBL] [Abstract][Full Text] [Related]
7. B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design. Cagigi A; Nilsson A; De Milito A; Chiodi F Vaccine; 2008 Jun; 26(24):3016-25. PubMed ID: 18164520 [TBL] [Abstract][Full Text] [Related]
12. Tailored immunogens for rationally designed antibody-based HIV-1 vaccines. Mouquet H Trends Immunol; 2015 Aug; 36(8):437-9. PubMed ID: 26169255 [TBL] [Abstract][Full Text] [Related]
13. Immunocytochemical determination of antigen and epitope specificity of HIV-1-specific B cells in lymph-node biopsies from HIV-1-infected individuals. Laman JD; Rácz P; Tenner-Rácz K; Klasmeier M; Fasbender MJ; Neelen C; Zegers ND; Dietrich M; Boersma WJ; Claassen E AIDS; 1991 Mar; 5(3):255-62. PubMed ID: 1711861 [TBL] [Abstract][Full Text] [Related]
14. Candidate multi-epitope vaccines in aluminium adjuvant induce high levels of antibodies with predefined multi-epitope specificity against HIV-1. Ding J; Lu Y; Chen Y FEMS Immunol Med Microbiol; 2000 Oct; 29(2):123-7. PubMed ID: 11024351 [TBL] [Abstract][Full Text] [Related]
15. Identification and specificity of broadly neutralizing antibodies against HIV. McCoy LE; Burton DR Immunol Rev; 2017 Jan; 275(1):11-20. PubMed ID: 28133814 [TBL] [Abstract][Full Text] [Related]
16. Challenges and opportunities for development of an AIDS vaccine. Nabel GJ Nature; 2001 Apr; 410(6831):1002-7. PubMed ID: 11309631 [TBL] [Abstract][Full Text] [Related]
17. HIV Broadly Neutralizing Antibodies: VRC01 and Beyond. Wu X Adv Exp Med Biol; 2018; 1075():53-72. PubMed ID: 30030789 [TBL] [Abstract][Full Text] [Related]
18. HIV-1-specific B cell activation. A major constituent of spontaneous B cell activation during HIV-1 infection. Amadori A; Zamarchi R; Ciminale V; Del Mistro A; Siervo S; Alberti A; Colombatti M; Chieco-Bianchi L J Immunol; 1989 Oct; 143(7):2146-52. PubMed ID: 2476498 [TBL] [Abstract][Full Text] [Related]
19. Predictions of linear T-cell and B-cell epitopes in proteins encoded by HIV-1, HIV-2 and SIVMAC and the conservation of these sites between strains. Zvelebil MJ; Sternberg MJ; Cookson J; Coates AR FEBS Lett; 1988 Dec; 242(1):9-21. PubMed ID: 2462515 [TBL] [Abstract][Full Text] [Related]
20. Novel approaches to peptide and engineered protein vaccines for HIV using defined epitopes: advances in 1994-1995. Berzofsky JA; Berkower IJ AIDS; 1995; 9 Suppl A():S143-57. PubMed ID: 8819581 [No Abstract] [Full Text] [Related] [Next] [New Search]